GSK Beats Q2 Estimates and Launches £1.9 Billion Efficiency Programme

Overview

• GSK reported quarterly revenue of £8.41 billion and adjusted EPS of 50.5 pence, both above analyst forecasts.
• Management unveiled a three-year £1.9 billion efficiency programme that it says will simplify the organisation and reallocate funds to late-stage pharmaceutical development.
• Specialty Medicines grew 14% and Vaccines rose 8% while General Medicines fell 9%, highlighting which businesses are driving near-term sales.
• The company confirmed a 17p quarterly dividend and pledged £400 million for UK investment including a new R&D centre, and shares rose about 4.2% on the news.
• GSK is using the savings push and recent deals such as the Nuvalent acquisition to bolster an oncology-led pipeline as it seeks to offset upcoming patent expiries and pursue a >£40 billion 2031 revenue ambition.